Molecular Docking Of Cyclosenegalin A As Anticancer
Article Sidebar
Main Article Content
Abstract
Cancer is recognized as a leading cause of death globally, responsible for approximately 14.5% of all deaths,. Cyclosenegalin A showed activity against DU-145 human prostate cancer cell line with IC50 of54.92.35μM. This study aims to investigate whether the cyclosenegalin A compound can interact with the target receptors 4IEH and potentially act as an anticancer candidate. The results of the study show that the docking of cyclosenegalin A with the 4IEH receptor yielded the best results, with an affinity value of -8.88 kcal/mol. The hydrogen bonding at the GLY 104, ASP 70, VAL 92, and GLU 95 amino acids was identical to that observed in the standard ligand, n-heteroarilsulfonamides. The interaction between cyclosenegalin A and the target receptor is effective, indicating that cyclosenegalin A holds potential as an anti-cancer candidate.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright and Licensing
For all articles published in Fullerene Journal of Chemistry, Authors retain some copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. In addition, the article may be reused and quoted provided that the original published version is cited. These conditions allow for maximum use and exposure of the work while ensuring the authors receive proper credit.
Authors are free to:
- Share - copy and redistribute the material in any medium or format
- Adapt - remix, transform, and build upon the material for any purpose, even commercially.
Under the following terms:
- Attribution - You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions - You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices: You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation. No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.